FindTrial
Sign In

Outcomes of initial Radioactive Iodine Therapy in Differentiated Thyroid Cancer Patients with and without a History of Graves’Disease

Outcomes of initial Radioactive Iodine Therapy in Differentiated Thyroid Cancer Patients with and without a History of Graves’Disease

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500105324
Enrollment
Unknown
Registered
2025-07-02
Start date
2025-07-05
Completion date
Unknown
Last updated
2025-07-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Differentiated Thyroid Cancer

Interventions

Graves' disease group:None
No Graves' disease group:None

Sponsors

The first affiliated hostipal of nanchang university
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1.Patients who underwent total thyroidectomy and were pathologically confirmed to have DTC. 2.Eligible for postoperative radioactive iodine (¹³¹I) therapy for thyroid cancer, as indicated in the 2015 American Thyroid Association (ATA) Guidelines for the Management of Thyroid Nodules and Differentiated Thyroid Cancer. 3.Follow-up duration >= 6 months.

Exclusion criteria

Exclusion criteria: 1.A history of other malignancies or other significant medical conditions. 2.Multiple courses of radioactive iodine (¹³¹I) treatment; 3.Incomplete follow-up data.

Design outcomes

Primary

MeasureTime frame
Single Photon Emission Computed Tomography (SPECT);Ultrasonography of the thyroid gland;Computed Tomography (CT);Thyroglobulin and related antibodies;—

Secondary

MeasureTime frame
Thyroid function;—

Countries

China

Contacts

Public ContactZeng Lingpeng

The first affiliated hostipal of nanchang university

863138869@qq.com+86 791 8869 2780

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026